Explore Apeloa’s Advanced Technology & Integrated Solutions at CPHI Frankfurt (Booth 9.1B64)

Posted on by

FRANKFURT, Germany, Oct. 27, 2025 — The global pharmaceutical sector convenes this week at CPHI Frankfurt 2025, taking place from October 28–30. Apeloa Pharmaceutical, a subsidiary of Hengdian Group and a prominent global provider of technology-driven pharmaceutical manufacturing solutions, extends a warm invitation to visit us at Booth 9.1B64.

We warmly encourage you to connect with our team to discuss how our comprehensive, end-to-end services can help expedite your projects, from their initial discovery phases through to commercialization.

Featuring Advanced Technology Platforms

As an enterprise driven by technology, Apeloa harnesses its cutting-edge platforms to bolster both its CDMO services and API manufacturing operations. Our primary platforms being showcased include:

Greener, Faster Molecules with Flow Chemistry: Apeloa’s advanced flow chemistry platform establishes a new environmental standard, serving as an alternative to conventional batch processing. We have demonstrated its effectiveness by reducing a key cephalosporin intermediate reaction time by 99% (from 8 hours to under 5 minutes), decreasing Process Mass Intensity (PMI) by 53%, and cutting energy consumption in half. This technology is particularly well-suited for high-risk or hazardous reactions and is supported by over 10 years of process development expertise and a team of 50+ specialized scientists.

Advancing Next-Gen Bioconjugates (ADCs/XDCs): Apeloa offers high-purity linkers and extensive chemistry services to accelerate your projects in ADC, targeted conjugation, and peptide drug development. Our areas of expertise include:

  • Monodisperse PEG Synthesis: We provide monodisperse PEGs with high purity (≥98%) and a precise polydispersity index of 1.00, available for scales ranging from R&D to multi-kilogram production.
  • Specialized Linkers: We offer a diverse collection of linkers, including PEG Linkers, Clickable Linkers, and MAL Linkers, along with modifications such as GGFG and PAB spacers, designed to improve stability and efficacy.

Apeloa Pharmaceuticals Hengdian R&D Center and Jiayuan Manufacturing Site

Comprehensive CDMO & Global API Solutions

These technological platforms form the backbone of our core business units, facilitating seamless, comprehensive support for our partners worldwide.

  • CDMO Services: As a vital participant in the global drug innovation ecosystem, Apeloa delivers comprehensive, one-stop CDMO services covering the entire life cycle of new drug development and commercialization. We enable clients globally to expedite the provision of affordable medications. Our adaptable, client-focused solutions encompass R&D preparation services (FTE/FFS) and dedicated support from laboratory-scale development through to full commercial production.
  • Global API Leadership: Apeloa stands as a leading international API supplier, characterized by its robust framework from R&D to commercialization and a vertically integrated supply chain spanning from intermediates to FDFs. Our diverse product portfolio includes anti-infectives, nervous system, cardiovascular system, and diabetes treatments. We leverage a powerful combination of fermentation and chemical synthesis for rapid scale-up. This integrated approach ensures stringent quality control, supported by 150 DMFs, 20 CEPs, and an annual capacity of 3,000 metric tons.

About Apeloa

Established in 1989, Apeloa is the pharmaceutical division of Hengdian Group and ranks among China’s top 2 API exporters and top 5 CDMO companies. Our principal business areas include API, CDMO, FDF, and Aesthetic & Care Ingredients (ACI), all underpinned by advanced technical platforms with over 1,300 scientists across R&D centers (Boston, Shanghai, Hengdian) and international branches (Germany, USA, Japan). Apeloa’s manufacturing facilities hold certifications from major global regulatory bodies (EDQM, US FDA, NMPA, PMDA, KFDA), having successfully passed 19 US FDA inspections since 2006, thereby ensuring high-quality and dependable service for partners worldwide.

Contact: